89 results about "ELAV Proteins" patented technology

Provided is a compound for double targeting of a fibroblast activation protein and an integrin subtype, comprising: (i) a chelating ligand moiety (CL); (ii) a first targeting moiety (BT); and (iii) a second targeting moiety (CY), wherein (i), (ii), and (iii) are fixed, combined, or connected by means of any L; BT is a fibroblast activation protein (FAP)-specific binding ligand structure; CY is an integrin subunit αvβ3 or αvβ6-specific binding ligand structure; L is selected from one or a combination of L1, L2, L3, L4, L5, L6, and L7; L1, L2, L3, L4, L5, L6, and L7 are each independently a key, a monovalent joint, a divalent joint, or a trivalent joint. Also provided are a preparation method for the compound and use thereof.

The invention relates to the technical field of compound preparation and medicine, in particular to a boron atom-labeled compound for targeting fibroblast activating protein as well as a preparation method and application of the boron atom-labeled compound. The preparation method comprises the following steps: carrying out acid amine condensation on (4-(((2, 5-dioxopyrrolidine-1-yl) oxy) carbonyl) phenyl) boric acid and an FAP targeting ligand to obtain a boron atom-labeled compound targeting the fibroblast activating protein; and the FAP targeting ligand is FAPI-46 or FAP-2286 (Fibroblast Amplified Polymorphism). The compound is easy to prepare, high in purity and good in stability, the content of boron atoms in tumor tissue can be greatly increased, and a treatment basis is provided for boron neutron capture therapy.

The present disclosure relates to pharmaceutical compositions comprising a [61Cu]Cu-labeled fibroblast activation protein (FAP) inhibitor-NODAGA conjugate. The present disclosure also relates to methods of imaging subjects suspected of having or diagnosed with a FAP-expressing cancer or tumor by administering the pharmaceutical compositions described herein and generating one or more radiographic images of the subject.

The invention discloses a method and application for single nucleotide polymorphism identification based on crRNA spacer splitting, by splitting the crRNA spacer complementary to the target base to obtain a recognition probe, when the recognition probe is fully complementary to the target sequence, Cas12a protein is activated to produce a significant fluorescent signal; when there is a base mismatched with the split spacer in the target sequence, the crRNA spacer of the split is difficult to assemble with the incomplete matching sequence, and the Cas12 system is not activated and does not produce a fluorescent signal. The method of the present invention enhances the high specificity recognition ability of CRISPR / Cas12a to single base mismatch, so that the detection of SNP is not limited by the position of the mismatched base, and still shows high resolution in low mutation abundance, for preparing a detection kit for single nucleotide mismatch, to meet the actual detection requirements for clinical samples.

The invention discloses a method for detecting mitochondria m.3243Agt, m.3243Agt. The invention relates to sgRNA, a kit and a method for detecting G mutation. The nucleic acid sequence of the sgRNA comprises a sequence as shown in SEQ ID NO. 1. The sgRNA which can be combined with LbCas12a protein and can be complementarily paired with a base of target nucleic acid is designed, the target nucleic acid with a PAM sequence is guided to be recognized and cleaved by an sgRNA-LbCas12a complex, so that the trans-cleavage activity of the LbCas12a protein is activated, a nucleic acid fluorescence report probe in a solution system is cut up, a detection fluorescence signal is released, and the process of detecting the target nucleic acid is completed. The detection specificity is good, the operation is simple, and the repeatability is strong.

The present invention relates to the field of radiopharmaceutical chemistry, and more particularly to a radioactive probe that targets fibroblast activation protein (FAP), a preparation method, and applications thereof. The structural formula of the compound targeting FAP provided by the present invention is: #imgabs0#. This compound possesses excellent radionuclide labeling properties. The resulting radioactive probe, a FAP inhibitor, can simultaneously target tumor-associated fibroblast activation protein (FAP) and bone metabolism-related targets, thereby improving diagnostic accuracy and specificity, increasing retention time and effectiveness, and enhancing treatment outcomes. This allows for more comprehensive diagnosis and evaluation of tumors and bone metastases, and is particularly suitable for patients with both primary tumors and bone metastases.

The invention refers to the use of PAP-I, a plant ribosome inactivating protein (RIP), or a functional variant thereof for treatment of human papillomavirus (HPV) infection and preventing or treating diseases or conditions associated with HPV infection.

The present invention provides novel RNA base editing compositions, systems, methods and uses. Guide RNAs for site-specific RNA editing of RNA encoding transcriptional coactivators YAP1 or TAZ are provided, and compositions and systems comprising the same with a programmable RNA binding protein (e.g. a Cas protein) and / or a base editor. Methods for RNA editing of YAP1 or TAZ are also provided. RNA editing of YAP1 or TAZ is used for targeting phosphorylation sites, and activating transcription of proteins in regenerative therapy for treating cardiac disease.

The invention discloses a protein capable of inducing a plant immune activation function and application of the protein in disease control, the gene sequence of the protein capable of inducing the plant immune activation function is shown as SEQ ID NO: 1, and the amino acid sequence of the protein is shown as SEQ ID NO: 2. According to the invention, a novel plant immune activator protein CgSsp16 secreted by colletotrichum gloeosporioides is identified, can be identified by plants, stimulates a plant immune response mechanism, triggers broad-spectrum resistance of host plants to various pathogens and improves disease resistance of various plants; the compound is expected to be developed into a novel biopesticide to be applied to green and sustainable production of agriculture.

A FAP glycopeptide as represented by Formula (I), and a radionuclide marker thereof and the use thereof. The FAP glycopeptide is obtained by modifying a linker portion that forms a cyclic peptide on the basis of a polypeptide FAP-2286 structure, and further introducing mono- or di-saccharide molecules. After being marked with radionuclides, the glycopeptide shows superior tumor uptake and lower liver uptake compared to FAP-2286, resulting in better imaging outcomes, facilitating the development of candidate radionuclide pharmaceuticals with further research value, and contributing to the ultimate goal of developing FAP-targeted cyclic peptide radiopharmaceuticals with independent intellectual property rights. Drawing_references_to_be_translated

The present invention relates to a method of determining the responsiveness of a cancer patient to treatment with a compound that inhibits a KRAS protein or a KRAS protein mutant or treatment with a compound that inhibits the interaction between MDM2 and p53, the method comprising measuring the survivin level in a first sample obtained from the patient prior to treatment with the compound, measuring the level of survivin in a second sample obtained from the patient during or after treatment with the compound, comparing the level of survivin in the second sample to the level of survivin in the first sample, and determining the level of survivin in the second sample when compared to the level of survivin in the first sample. When the survivin level in the second sample decreases, it is determined that the patient is responsive to treatment with the compound. The invention further relates to the use of survivin in compounds for determining the inhibition of KRAS protein or KRAS protein mutants, or in compounds for inhibiting the interaction between MDM2 and p53, or a pharmaceutical formulation comprising said compound that inhibits a KRAS protein or a KRAS protein mutant or said compound that inhibits an interaction between MDM2 and p53 in a method of treating cancer.

The present invention relates to a multispecific antibody comprising at least a FAP [alpha] binding region comprising a first heavy chain variable region and a first light chain variable region and a DR4 binding region comprising a second heavy chain variable region and a second light chain variable region. The invention further provides pharmaceutical compositions comprising the antibodies and the use of the antibodies for therapeutic and diagnostic procedures, particularly in cancer therapy.

The application discloses a SIRT protein promoter and application thereof, and belongs to the technical field of cosmetics, and particularly relates to a SIRT protein promoter; the active ingredient of the SIRT protein promoter is oligopeptide-6; the oligopeptide-6 can not only activate an AMPK signal path, up-regulate NAMPT gene expression, and improve intracellular NAD + level, thereby activating SIRT protein in dependence on NAD + ; and can effectively promote collagen production, and realize the effects of anti-wrinkle and skin tightening.

The present invention relates to new ubiquitin-derived molecules that specifically bind to fibroblast activation proteins (FAPs). The invention further relates to FAP-binding ubiquitin-derived molecule (Affilin®) proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover such FAP-binding proteins for use in medicine, e.g. for use in the diagnosis (including imaging) or treatment of FAP-associated tumors.

The invention discloses a kit and a method for rapidly and visually detecting grapefruit moth based on RPA-CRISPR / Cas12a. The kit comprises a recombinase polymerase amplification primer and a targeting crRNA sequence, and the amplification primer can specifically amplify a target nucleotide sequence derived from a grapefruit botryosphaeria maculata mitochondrial genome; the primer comprises an upstream primer and a downstream primer, the sequence of the upstream primer is as shown in SEQ ID NO: 1, and the sequence of the downstream primer is as shown in SEQ ID NO: 2; the target crRNA sequence can be specifically combined with a target nucleotide sequence generated by amplification of the RPA primer and activate the bypass cleavage activity of Cas12a protein, and the sequence of the target crRNA is as shown in SEQ ID NO: 3. The detection kit disclosed by the invention has the characteristics of strong specificity, high speed and high sensitivity, and can be used for detecting grape fruits at the initial stage of being infected by the grapefruit botryosphaeria hemsleyana.

The present disclosure provides combination therapies for treating a cancer having a BRAF mutation, the combination therapies comprising administering to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1 / 2 inhibitor; (c) a cyclin-dependent kinase (CDK) 4 / 6 inhibitor. Also provided are compositions and kits related to the combination therapies.

The present invention is related to bispecific antigen binding molecules that specifically bind to Activin A and GDF8, and therapeutic and diagnostic methods of using those molecules.

The invention discloses an RPA-CRISPR / Cas12a system for detecting a cowfish based on environmental DNA (Deoxyribonucleic Acid) and a specific primer, and belongs to the technical field of biological detection. Aiming at the sequence of a COI fragment of a mitochondrial genome of the Jiangsu, an RPA primer with the species specificity of the Jiangsu is designed so as to amplify a target fragment; designing a high-activity and specific crRNA sequence by searching a Cas12a protein recognition site in a corresponding amplification sequence so as to guide the Cas12a protein to recognize a target fragment and activate the trans-cleavage activity of the Cas12a protein; by designing a molecular probe with stable performance, the probe is stably and efficiently cut by a Cas12a-crRNA active compound, and a detection result can be observed in real time through a luminoscope. The detection method is easy to operate, high in sensitivity and good in specificity, detection can be completed only through constant-temperature heating equipment, and a new technology and method are provided for rapid detection and protection of the cowfish.

A method of treating a target tissue area with a ribosome-inactivating protein. The method comprises injecting the target tissue area with an effective dose of a ribosome-inactivating protein and administering electroporation therapy to the target tissue area.

The present invention relates to a multispecific antibody comprising a FAPα-binding region comprising at least a first heavy chain variable region and a first light chain variable region, and a DR4-binding region comprising a second heavy chain variable region and a second light chain variable region. The invention further provides pharmaceutical compositions comprising the antibody, and uses of the antibody in therapeutic and diagnostic procedures, particularly in cancer treatment.

Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange / hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration / diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.

The technology relates to polypeptides comprising a scaffold comprising a sequence having at least 90% identity to the amino acid sequence of human Stefin A, wherein the scaffold sequence includes (a) an insertion of an amino acid between amino acid positions corresponding to M1 and I2 of the amino acid sequence of human Stefin A and (b) a mutation at an amino acid position corresponding to N32 of the amino acid sequence of human Stefin A, and a heterologous peptide. The technology also relates to human Stefin A variants that bind to fibroblast activation protein alpha and / or human serum albumin.

The application discloses a non-coding RNA detection kit based on CRISPR / CtCas12a and reverse transcriptase and application, and belongs to the technical field of gene detection. When the non-coding RNA detection kit provided by the application detects a to-be-detected non-coding RNA sequence, the CtCas12a protein will cut the detection probe modified by LNA and release a 6nt single-stranded DNA, the single-stranded DNA and the RT-spacer are combined into a hybrid double-stranded DNA under the action of reverse transcriptase, and then the trans-cleavage activity of the CtCas12a protein is activated again, a fluorescence signal is released, and signal autocatalysis amplification triggered by a target is realized. The application enhances the cutting specificity and improves the detection sensitivity through LNA modification. In addition, through the replaceable ssDNA activator sequence, different target detection requirements can be adapted, and the cost of the detection system is reduced. Therefore, the application has a good application prospect in non-coding RNA detection.

The invention provides a near-infrared fluorescence activated protein, a gene containing the near-infrared fluorescence activated protein, an expression box and a using method thereof, and a cell and a kit for generating the near-infrared fluorescence activated protein. A compound formed after the near-infrared fluorescence activated protein is combined with a corresponding fluorescent ligand has strong fluorescence, the fluorescence excitation peak wavelength is 574nm, near-infrared light with the emission peak wavelength is 680nm, and the near-infrared fluorescence activated protein has the advantages of high fluorescence quantum yield, large two-photon absorption cross section and the like, and has the advantage of high signal-to-noise ratio in vitro, living cells and living animals.

Oligonucleotides and compositions including the same are disclosed that modulate (e.g., inhibit, limit or reduce) sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP) activity. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders, and / or conditions associated with SCAP activity such as nonalcoholic fatty liver disease (NAFLD), (NASH), dyslipidemia, atherosclerotic cardiovascular disease (ASCVD), and / or other SCAP-associated conditions, diseases, and / or disorders.

The invention relates to the technical field of nucleic acid detection, and discloses a method and a device for detecting and distinguishing ginseng and American ginseng and terminal equipment, and the method comprises the following steps: enriching specific DNA fragments of ginseng and American ginseng by using a multi-enzyme isothermal amplification technology, and screening high-specificity crRNA by combining with a PAM sequence of Cas protein. During detection, a two-channel detection system is constructed by using crRNA, Cas protein and a test probe; after the crRNA accurately recognizes a target sequence in a to-be-tested sample according to a base complementation principle, the trans-cleavage function of the Cas protein is activated, and the test probe is cleaved to form a visual signal. Through two-channel logic, not only can single species be identified, but also a mixed adulteration sample can be identified, the method has the advantages of high sensitivity, strong specificity, constant temperature in the whole process, no need of a precise variable temperature instrument and the like, the problem of interference of near-source species is effectively solved, and simple, convenient and rapid detection of ginseng and American ginseng is realized.

An anti-fibroblast activation protein alpha (FAP) polypeptide comprising at least one single-domain antibody directed against FAP. A pharmaceutical composition comprising an anti-FAP single-domain antibody conjugated to a radioisotope at a ratio that maximizes specific activity but does not compromise affinity. A method of reducing a tumor is a subject in need thereof, comprising administering the pharmaceutical composition to a subject.

The invention provides an IgG (immunoglobulin G) binding type immune activator protein as well as a preparation method and application thereof, and belongs to the technical field of medicines. It is found for the first time that after three Fab binding peptides CFab and N215 are fused, the N215 can be endowed with the IgG antibody binding capacity, the obtained fusion protein N215-CFab3 and the IgG antibody can form a stable compound, and the compound retains the functions of the N215 and the antibody, can mediate binding of the N215 to target cells, remarkably prolongs the half-life period of the N215, promotes proliferation of T and NK cells, and has the advantages of being capable of achieving the purpose of improving the immunogenicity of the N215 and improving the immunogenicity of the N215. The remarkably enhanced in-vivo anti-tumor effect is exerted. A compound formed by the fusion protein N215-CFab3 and an IgG antibody can be used as an immune activator, and has a wide application prospect in immunotherapy of diseases such as tumors and infection.

In general, the current disclosure relates to sterol regulatory element-binding protein cleavage-activating protein (SCAP) affecting endoplasmic reticulum ribosome translation.

The application provides a gallium-68 / lutetium-177 / terbium-161 labeled cysteine modified FAPI complex and a preparation method and application thereof, and belongs to the technical field of cysteine modified complexes. 68 Ga / 177 Lu / 161 Tb‑FAPI‑Cys, and two steps of preparation of the Tb‑FAPI‑Cys are carried out to obtain 68 Ga / 177 Lu / 161 Tb‑FAPI‑Cys complex. The complex is simple to prepare, has high radiochemical purity and good stability, has high tumor uptake, high target-to-background ratio in a fibroblast activation protein (FAP) high expression tumor model, can be specifically targeted to a tumor site, and is a new type of tumor radioactive drug with clinical application value.